[HTML][HTML] Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans

AP Doumatey, AR Bentley, J Zhou… - … of endocrinology and …, 2012 - ncbi.nlm.nih.gov
AP Doumatey, AR Bentley, J Zhou, H Huang, A Adeyemo, CN Rotimi
Journal of endocrinology and metabolism, 2012ncbi.nlm.nih.gov
Background It has been suggested that adiponectin may offer protection against the adverse
health effects of obesity. In this study, we determined the prevalence of paradoxically high
adiponectin or paradoxical hyperadiponectinemia (PHA) among obese African Americans
and investigated its relationship with the metabolically healthy obese (MHO) phenotype.
Methods Total adiponectin and metabolic markers including fasting glucose, insulin, serum
lipids and obesity measures were determined in 822 unrelated participants from the Howard …
Abstract
Background
It has been suggested that adiponectin may offer protection against the adverse health effects of obesity. In this study, we determined the prevalence of paradoxically high adiponectin or paradoxical hyperadiponectinemia (PHA) among obese African Americans and investigated its relationship with the metabolically healthy obese (MHO) phenotype.
Methods
Total adiponectin and metabolic markers including fasting glucose, insulin, serum lipids and obesity measures were determined in 822 unrelated participants from the Howard University Family Study (HUFS). Logistic regression models were used to evaluate the association between MHO phenotype and PHA while adjusting for relevant covariates.
Results
Overall, men had significantly lower adiponectin levels than women. However, adiponectin level was associated with obesity measures, glucose, insulin and insulin resistance index in both men and women. Equal proportion of the obese male and female subjects (19.2%; 66/343) had PHA; these obese individuals with PHA had a healthier metabolic profile including higher HDL-cholesterol, lower insulin levels and smaller waist circumference and insulin levels compared to those without PHA. Also, 28%(96/343) of the study participants met the criteria of MHO phenotype. Interestingly, 42%(28/66) of the obese individuals with PHA also had the MHO phenotype. Finally, the MHO phenotype was associated with PHA in both men and women.
Conclusions
These findings confirm the presence of MHO in African Americans and demonstrate the association of PHA with the MHO phenotype. In all, our findings along with other published results provide evidence for a more systematic investigation of the mechanisms underlying the protective function of adiponectin and its potential therapeutic applications in human metabolic disorders.
ncbi.nlm.nih.gov